Wellnex Life Limited (Wellnex, WNX or Company) (ASX:WNX), owner and developer of some of Australia's leading health brands, has recently published key ASX announcements.
Company Update - Wellnex to dual list on the London Stock Exchange
Announcement Highlights
- Wellnex has commenced the process to dual list on the London Stock Exchange that will provide a pathway to accelerate our growth both domestically and internationally.
- Wellnex has appointed UK based Strand Hanson as Financial Advisor for the dual listing on the London Stock Exchange.
- Barclay Pearce Capital and UK based Orana Corporation have been appointed as joint-lead brokers for the dual listing,
- Wellnex listing on the London Stock Exchange will capitalise on our international growth on the back of:
1. Haleon taking our products to the Middle East and European markets.
2. Homart Pharmaceuticals disturbing our brands throughout Asia. - Dual listing provides greater exposure to a larger pool of institutional investors.
Wellnex Life Ltd(ASX: WNX, 'Wellnex', or 'the Company'), an Australian consumer healthcare company working to deliver health, wellness, and vitality solutions to a global marketplace, is please to provide an update on the London Stock Exchange listing first announced to the market in a company update on 5 October 2023.
Since the announcement, Wellnex has conducted extensive due diligence and analysis on the opportunity, including an institutional roadshow, and the Board is pleased to announce that it has appointed UK advisors to dual list the Company's shares on the London Stock Exchange(LSE) in 2024.
Listing on the LSE will provide a platform to continue to grow the company both domestically and internationally and comes at a time where Wellnex will shortly commence taking our brands and products and brands to new international markets.
Read the full Wellnex Life Company Update here.
Chairman's Letter
Wellnex's CEO George Karafotias commented:
"I am pleased to take this opportunity as your Chair to share with you an update on the recent developments and progress of Wellnex Life on behalf of the Board and Management.
Since my appointment as Non-Executive Chair in December 2023, my fellow directors and I have been heavily involved in strategising the next phase of growth at Wellnex by leveraging our collective consumer health and wellness industry experience.
The year to-date has been incredibly busy for the Wellnex team, particularly with the integration of Pain Away post acquisition in December 2023. I am particularly proud of how our new board has quickly united to support our management team, ensuring alignment and commitment to delivering value for all stakeholders."
Read the full Wellnex Life Chairman's Letter here.
To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.
